Dear Sir,

In early December 2019, a severe acute respiratory infection was firstly reported in Wuhan and then recognized as coronavirus disease 2019 (COVID-19). Currently, COVID-19 has quickly triggered a devastating pandemic outbreak, raising the global panic and concern [1, 2]. The confirmed cases keep rising in many countries, including Italy, Iran, and Spain. The World Health Organization (WHO) has declared the COVID-19 a public emergency of international concern [3]. Until March 22, 2020, more than 290,000 confirmed cases and over 12,000 deaths had been documented globally [3].

The pathogen of COVID-19 has been identified as a novel enveloped RNA β-coronavirus named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [4], which has a phylogenetic similarity to SARS-CoV [5]. COVID-19 is spread mainly by respiratory droplets and direct contact. The main pathogenesis of COVID-19 was severe pneumonia, RNAemia, combined with the incidence of ground-glass opacities and acute cardiac injury, with fever and cough as the most common symptoms [2]. Confirmation of the infection is based on positive nucleic acid testing of respiratory tract samples (e.g., throat swabs) [6], and clinical diagnosis can be made as per symptoms, exposures, and chest computed tomography (CT).

In response to the WHO statements and international concerns regarding the COVID-19 outbreak, the Chinese Society of Nuclear Medicine (CSNM) promptly put forward a consensus on the management of nuclear medicine care (NM care) during the COVID-19 epidemic [7]. Meanwhile, the NM Committee of the Chinese Society of Clinical Oncology (CSCO-NM) has taken the lead in initiating the online counseling platform for patients who need NM for further diagnosis and treatment, as well as the follow-ups after NM therapy. All the reactions were made to maximumly reduce the risk of probable disease infection or transmission while preserving the quality of NM care. Considering the current severe global pandemic, it is necessary to share the key points of the actions of NM healthcare personnel (HCP) in China to our colleagues of the whole world. We hope they could provide our colleagues worldwide with informative guidance in this critical period to cope with the COVID-19 pandemic crisis.

COVID-19 prevention and control measures during the NM care

NM care for outpatients

To minimize the probable risk of exposures, measures should be implemented throughout the NM care for outpatients (Table 1).
To minimize the potential risk of COVID-19 infection/transmission during hospitalization, specific strategies were put forward as follows except the routine care and precautions for radiation exposure:

- Inquiries about the symptoms (unexplained fever, cough, diarrhea, etc.) and risk factors (travel history of epidemic areas, and history of intimate contact and cluster) should be made for all patients upon hospitalization. The suspected/confirmed cases should be advised to postpone NM treatment and transferred to designated tertiary hospitals or isolation wards specified for COVID-19 treatment.
- Patients’ body temperature should be regularly checked and recorded during hospitalization. And patients should be under close observation for unexplained fever, cough, diarrhea, and other symptoms related to the COVID-19 infection. Patients with any of the probable symptoms mentioned above should be immediately quarantined, and in-hospital consultation with the respiratory specialists should be promptly conducted to guild further assessment and treatment.
  - Upon the suspected/confirmed patients’ transference or normal patients’ discharge, the room should undergo appropriate cleaning and disinfection before it is available for routine use [8].
  - Specific instructions on personal hygiene related to COVID-19 should be provided for patients during hospitalization.

**Online NM counseling platforms**

To reduce the potential risk of exposures during the commuting, provide NM care and alleviate the possible anxiety for patients who are going to receive NM imaging/treatment or post-NM therapy follow-ups; the CSCO-NM advocated and initiated an online voluntary counseling platform for the postsurgical management of differentiated thyroid cancer (DTC) on February 16, 2020 [9]. It was then followed by...
collaborations from other academic associations, including the Thyroid Cancer Committee of CSCO, CSNM, Beijing Quality Control and Improvement Center for NM, and NM Diagnosis and Treatment Committee of Beijing Precision Radiology Society, expanding the online counseling to all NM care–related queries.

In the DTC management app [10], NM experts from 21 provinces of China were posted to voluntarily provide counseling; modules were designed for patients to provide their medical information and counseling purposes; meanwhile, simplified questionnaires were applied to evaluate the psychological status of each patient ahead of the online communications (Fig. 1). The detailed steps for patients to enter were as follows:

1. Medical information collection
   • Surgical information, including the date and manner of surgery, as well as the pathological findings.
   • Post-surgical information before radiiodine (RAI) therapy: (1) recent serum biochemical results, including thyroid-stimulating hormone (TSH), thyroglobulin (Tg), and thyroglobulin antibody (TgAb); (2) recent imaging results, such as cervical ultrasound, chest CT, or 131I-whole body scan (WBS).
   • RAI therapy information: (1) received RAI therapy or not? (date and dose) (2) levothyroxine dose after RAI therapy.

2. Purpose of the online counseling

3. Psychological status self-assessment
   • Self-rating Anxiety Scale (SAS): 20 questions were included, and patients could be classified as no, mild, moderate, or severe anxiety;
   • Self-rating Depressive Scale (SDS): 20 questions were included, and patients could be classified as no, mild, moderate, or severe depression.

During the COVID-19 pandemic, DTC patients were counseled online mainly for their concerns about the necessity of RAI therapy according to the pathological findings, the possible impact of delayed RAI therapy or follow-ups, and the potential side effects of RAI therapy. These concerns reflected the deficiency of post-surgical guidance for DTC patients, leading to their poor awareness of the disease status, and underlined the significance of informing and popularization in the post-surgical management of DTC. Therefore, at this critical period, we should not only balance the benefit of NM care and the potential risk of COVID-19 exposures through online platforms, but also prioritize patients who need urgent NM care as per their risk of disease recurrence, which is based on patients’ latest serum biomedical and imaging assessments. Moreover, for the convenience of patients’ access to local NM care, there was also a patient’s location-based counseling which can be easily referred to among online NM experts. All in all, the online counseling platform minimized the potential risk of COVID-19 exposures during patients’ commuting for face-to-face NM inquiries, reassured patients’ access to handy NM resources, further normalized the system of future online NM care for DTC patients, enhanced the collaborations of NM professionals nationwide, and balanced the regional differences of NM resources.

According to incomplete statistics, as of March 22, 2020, over 2000 DTC patients throughout China have received helpful medical advice from such online platforms, indicating them as effective alternatives for the face-to-face NM care in the COVID-19 pandemic. Meanwhile, it was an effective way for us to learn patients’ real needs and worries, and these
voluntary actions reflected the collaboration and dedication of NM HCP in this critical period.

In addition, informative online training on the precautions of COVID-19 during NM care was also delivered through various social media such as WeChat and Weibo [11]. And popularization science articles were further generalized to favor patients to learn more about the management of NM care in this special period [12].

Retrospective NM findings of COVID-19

In retrospective studies, Qin et al. [13] and Zou et al. [14] have reported the 18F-FDG PET/CT findings in COVID-19 patients. 18F-FDG PET/CT characteristics of COVID-19 included the high 18F-FDG uptake in lung lesions, and nodal involvement were illustrated, further revealing the metabolic and systemic features of COVID-19.

Conclusions

In response to the COVID-19 outbreak, NM HCP promptly made a series of reactions, including hospital-based prevention/control measures as well as online medical counseling and training. Those actions have played a crucial role in reducing the potential risk of exposures during the NM care while preserving its function and quality. We sincerely appreciate the cooperation from all the HCP and patients. And we hope that the reactions from NM HCP in China could provide informative guidance for our global colleagues to cope with this pandemic crisis.

Acknowledgments

We appreciate the efforts from all the NM HCP of China, and cooperation from patients. We also appreciate the collaboration from the Goodwill Hessian Health Technology Company in making the online counseling app and the assistance of Dr. Ying-Qiang Zhang in making illustrations for this article.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval This article did not contain any studies with human participants performed by any of the authors.

References

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2001316.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.
3. Coronavirus disease (COVID-19) outbreak. https://www.who.int. Accessed 22 March 2020.
4. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74. https://doi.org/10.1016/S0140-6736(20)30251-8.
5. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33. https://doi.org/10.1056/NEJMoa2001017.
6. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance. https://www.who.int/docs/default-source/coronavirus/clinical-management-of-novel-cov.pdf. Accessed 20 March 2020.
7. Chinese Society of Nuclear Medicine, Editorial Board of Chinese Journal of Nuclear Medicine and Molecular Imaging. Expert consensus on the safety prevention and control of nuclear medicine diagnosis and treatment during the outbreak of COVID-19 (1st edition). Chin J of Nucl Med and Mol Imaging. https://doi.org/10.3760/cma.j.cn321828-20200222-00062.
8. Interim infection prevention and control recommendations for patients with suspected or confirmed coronavirus disease 2019 (COVID-19) in healthcare settings. https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html. Accessed 21 March 2020.
9. Fighting against COVID-19: the online voluntary counseling from top thyroid cancer experts. https://apps.apple.com/cn/app/calvary-bible-church/id1498342359. Accessed 15 March 2020.
10. Post-surgical management of differentiated thyroid cancer. https://apps.apple.com/cn/app/calvary-bible-church/id1498342359. Accessed 15 March 2020.
11. Shi HC. Prevention and control plans in PET examination during COVID-19. https://mp.weixin.qq.com/s/TyQud0cvqxRJj8N VAPwxEQ. Accessed 20 March 2020.
12. Lin YS. The role of nuclear medicine in the treatment of differentiated thyroid cancer. https://mp.weixin.qq.com/s/fb6U4GczA8r _4pK_Y6OqJw. Accessed 20 March 2020.
13. Qin C, Liu F, Yen TC, Lan X. (18)F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020- 04734-w.
14. Zou S, Zhu X. FDG PET/CT of COVID-19. Radiology. 2020;200770. https://doi.org/10.1148/radiol.2020200770.